Physician profile
Vu Phan
NPI 1437539988
$1,033.62
in general payments reported to CMS, 2019-2025
11 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $136 · 2021: $124 · 2022: $132 · 2023: $37.86 · 2024: $69.72 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $301.12 | 2019-2020 | |
| Glaxosmithkline, LLC. | $219.56 | 2024-2025 | Jemperli, Ojjaara, Zejula |
| Seagen INC. | $119.27 | 2021-2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $97.39 | 2019-2022 | |
| Celgene Corporation | $91.13 | 2022-2023 | Pomalyst |
| Astrazeneca Pharmaceuticals Lp | $69.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $66.35 | 2019-2020 | |
| Exelixis INC. | $48.16 | 2021-2022 | |
| Heron Therapeutics, INC. | $20.91 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.